Literature DB >> 17187492

Bupropion for weight reduction.

Kishore M Gadde1, Glen L Xiong.   

Abstract

Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients. The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187492     DOI: 10.1586/14737175.7.1.17

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

Review 1.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 2.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

3.  D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.

Authors:  B Kalyanasundar; Claudia I Perez; Alvaro Luna; Jessica Solorio; Mario G Moreno; David Elias; Sidney A Simon; Ranier Gutierrez
Journal:  J Neurophysiol       Date:  2015-05-13       Impact factor: 2.714

4.  Combination pharmaceutical therapies for obesity.

Authors:  Kishore M Gadde; David B Allison
Journal:  Expert Opin Pharmacother       Date:  2009-04       Impact factor: 3.889

5.  The effect of N-acetylcysteine or bupropion on methamphetamine self-administration and methamphetamine-triggered reinstatement of female rats.

Authors:  Sergios Charntikov; Steven T Pittenger; Cindy M Pudiak; Rick A Bevins
Journal:  Neuropharmacology       Date:  2018-03-28       Impact factor: 5.250

Review 6.  Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review.

Authors:  Claudia D'Alessandro; Alessia Benedetti; Antonello Di Paolo; Domenico Giannese; Adamasco Cupisti
Journal:  Nutrients       Date:  2022-01-04       Impact factor: 5.717

7.  Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues.

Authors:  G-J Wang; D Tomasi; N D Volkow; R Wang; F Telang; E C Caparelli; E Dunayevich
Journal:  Int J Obes (Lond)       Date:  2013-08-08       Impact factor: 5.095

Review 8.  Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review.

Authors:  Agnieszka Kulak-Bejda; Grzegorz Bejda; Napoleon Waszkiewicz
Journal:  Arch Med Sci       Date:  2020-09-10       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.